Drug Trial Radar · NCT05272384
Testing the Combination of Nivolumab and ASTX727 for Relapsed or Refractory B-Cell Lymphoma
Last checked: Nov 20, 2026Latest source record: Nov 18, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
32
Planned (sponsor's estimate)
Start
Nov 3, 2022
Primary completion
Jun 28, 2027
Study completion Jun 28, 2027
Sponsor
- Lead sponsor
- National Cancer Institute (NCI)NIH
- Sponsor type
- NIH
- First posted
- Mar 9, 2022
Design
- Study type
- Interventional
- Phase
- Phase 1
- Allocation
- Not applicable (single group)
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This phase I trial tests the safety, side effects, and best dose of nivolumab in combination with ASTX727 in treating B-cell lymphoma that has come back (relapsed) or does not respond to treatment (refractory). Immunotherapy with monoclonal antibodies, such as nivolumab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. ASTX727 consists of the combination of decitabine and cedazuridine. Cedazuridine is in a class of medications called cytidine deaminase inhibitors. It prevents the breakdown of decitabine, making it more available in the body so that decitabine will have a greater effect. Decitabine is in a class of medications called hypomethylation agents. It works by helping the bone marrow produce normal blood cells and by killing abnormal cells in the bone marrow. Giving nivolumab in combination with ASTX727 may shrink and stabilize cancer.
Conditions
- Recurrent B-Cell Non-Hodgkin Lymphoma
- Recurrent Diffuse Large B-Cell Lymphoma
- Recurrent Hodgkin Lymphoma
- Refractory B-Cell Non-Hodgkin Lymphoma
- Refractory Diffuse Large B-Cell Lymphoma
- Refractory Hodgkin Lymphoma
Interventions
Biospecimen CollectionProcedure
Undergo collection of blood samples
Computed TomographyProcedure
Undergo PET/CT
Decitabine and CedazuridineDrug
Given PO
NivolumabBiological
Given IV
Positron Emission TomographyProcedure
Undergo PET/CT
Primary outcomes
What the sponsor says the trial is designed to measure.
- Incidence of adverse eventsTime frame: Up to 2 years
Locations
9 sites in 1 country. Site status is shown where the registry gives one.
University of Alabama at Birmingham Cancer Center
Birmingham, Alabama · Active not recruiting
City of Hope Comprehensive Cancer Center
Duarte, California · Recruiting
University of California Davis Comprehensive Cancer Center
Sacramento, California · Recruiting
Yale University
New Haven, Connecticut · Recruiting
University of Chicago Comprehensive Cancer Center
Chicago, Illinois · Recruiting
UC Comprehensive Cancer Center at Silver Cross
New Lenox, Illinois · Recruiting
University of Chicago Medicine-Orland Park
Orland Park, Illinois · Recruiting
NYU Langone Hospital - Long Island
Mineola, New York · Recruiting
Laura and Isaac Perlmutter Cancer Center at NYU Langone
New York, New York · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.